Single-dose @entity7265 therapy for XXXX and @entity697 with bladder bacteriuria.

@entity1 @entity697 @entity115 @entity793 @entity281 @entity7265 @entity207 @entity293 @entity206
The efficacy of single-dose therapy with 3 g of @entity7265 was evaluated in 129 @entity1 with symptoms of acute uncomplicated lower @entity293 . Of 91 @entity1 with significant @entity793 , 61 (67%) were cured of their original infection; this was similar to the 54 to 79% cure rates reported in unselected populations of @entity1 of a wide age range treated for @entity293 with a single dose of @entity115 or @entity206 - @entity207 (J. Rosenstock, L. P. Smith, M. Gurney, K. Lee, W. G. Weinberg, J. N. Longfield, W. B. Tauber, and W. W. Karney, Antimicrob. Agents Chemother. 27:652-654, 1985; N. E. Tolkoff-Rubin, M. E. Wilson, P. Zuromskis, I. Jacoby, A. R. Martin, and R. H. Rubin, Antimicrob. Agents Chemother. 25:626-629, 1984). The cure rates of (87%) for our younger @entity1 , those less than 25 years of age, was better than that (46%) for our @entity1 over 40 years of age (P less than 0.001). @entity1 with @entity281 that were negative in an antibody-coated bacteria test were cured at a significantly higher rate than those with @entity281 that were positive in an antibody-coated bacteria test (71 versus 19%; P = 0.003). Those @entity1 with @entity281 caused by @entity7265 -susceptible organisms were cured at a rate similar to that for @entity1 with @entity281 caused by @entity7265 -resistant organisms (68 versus 50%; P = 0.62). The cure rate for suburban @entity1 was 90%, versus 45% for inner-city @entity1 (P = 0.008). Of the 28 @entity1 with @entity697 due to low-level @entity793 , 27 were cured.
